KAEL looks to make good on GemVax acquisition
This article was originally published in Scrip
Executive Summary
The South Korean company KAEL-GemVax continues to see significant commercial potential for a cancer vaccine it acquired from Pharmexa last year, despite the therapy's failure in one Phase III trial.